sever
communityacquir
pneumonia
cap
associ
high
mortal
rate
signific
morbid
patient
present
hospit
cap
requir
critic
care
admiss
streptococcu
pneumonia
continu
common
infect
pathogen
staphylococcu
aureu
legionella
gramneg
pathogen
increasingli
frequent
caus
pathogen
combin
viral
bacteri
infect
may
induc
sever
spectrum
diseas
sever
communityacquir
pneumonia
cap
remain
frequent
reason
admiss
hospit
common
caus
septic
shock
requir
escal
treatment
within
intens
care
unit
icu
despit
earlier
recognit
recent
advanc
support
care
sever
cap
still
associ
substanti
morbid
mortal
often
seen
elderli
consider
comorbid
cap
defin
acut
infect
pulmonari
parenchyma
symptom
onset
commun
diagnosi
still
made
within
h
hospit
admiss
meet
criteria
communityacquir
infect
sever
cap
defin
pneumonia
requir
support
therapi
within
critic
care
environ
associ
higher
mortal
rate
sever
cap
frequent
multisystem
diseas
patient
often
present
multipl
organ
failur
annual
incid
cap
per
adult
popul
europ
patient
requir
hospit
admiss
treat
cap
requir
icu
admiss
incid
cap
increas
age
death
relat
sever
pneumonia
occur
patient
age
day
mortal
rate
patient
admit
critic
care
increas
requir
invas
mechan
ventil
develop
septic
shock
mortal
rate
younger
patient
influenc
sever
infect
rather
presenc
comorbid
even
absenc
comorbid
sever
cap
associ
excess
mortal
subsequ
year
among
survivor
independ
age
cap
classic
present
triad
infect
sign
fever
leucocytosi
clinic
sign
symptom
sputum
product
tachypnoea
cough
pleurit
chest
pain
new
chang
infiltr
observ
radiographi
explan
except
infect
howev
clinic
sign
symptom
may
univers
seen
present
typic
particularli
elderli
immunosuppress
diagnosi
cap
may
cloud
complic
underli
diseas
state
affect
cardiorespiratori
function
atyp
subacut
present
infect
pneumonia
develop
defens
mechan
within
lung
becom
overwhelm
pathogen
either
inhal
aspir
like
occur
virul
pathogen
patient
reduc
host
defenc
pathogen
respons
cap
vari
widerang
capac
caus
sever
diseas
extrapulmonari
featur
streptococcu
pneumonia
gramposit
capsul
organ
infect
risk
highest
immunocompromis
elderli
hyposplen
patient
although
overal
frequenc
reduc
due
vaccin
pathogen
clinic
respons
infect
relat
pneumococc
virul
factor
genet
background
patient
indic
believ
alter
system
inflammatori
respons
produc
pneumococc
infect
although
overal
incid
penicillin
resist
reduc
adult
antibioticresist
pneumonia
may
seen
sever
patient
group
includ
sever
ill
patient
admit
icu
extrem
age
patient
recent
receiv
therapi
immunosuppress
patient
alcohol
patient
medic
comorbid
staphylococcu
aureu
gramposit
aerob
coagulaseposit
diplococcu
resist
strain
methicillinresist
st
aureu
mrsa
increasingli
isol
patient
diagnos
sever
pneumonia
although
surveil
erad
among
atrisk
patient
success
reduc
incid
mrsa
treat
antibiot
vancomycin
linezolid
teicoplanin
rifampicin
although
resist
vancomycin
increas
communityacquir
mrsa
camrsa
pneumonia
may
occur
previous
healthi
patient
prior
healthcar
exposur
often
influenza
predispos
sever
necrot
pneumonia
incid
camrsa
current
remain
low
need
consider
younger
patient
requir
physiolog
support
sever
cap
pantonvalentin
leukocidin
pvl
exotoxin
also
refer
toxigen
st
aureu
strongli
associ
virul
strain
st
aureu
pvl
gene
carri
mrsa
methicillinsensit
st
aureu
mssa
pvlsa
strain
current
mssa
although
increas
associ
camrsa
infect
pvlsa
strain
usual
associ
communityacquir
infect
produc
particularli
sever
form
haemorrhag
pneumonia
often
preced
flulik
ill
necrot
soft
tissu
infect
tabl
antimicrobi
linezolid
clindamycin
thought
effect
suppress
toxin
product
viral
infect
increasingli
common
caus
sever
cap
account
case
recent
year
seen
appear
sever
virul
respiratori
strain
caus
sever
pneumon
diseas
progress
multiorgan
failur
includ
avian
influenza
viru
middl
east
respiratori
syndrom
coronaviru
merscov
influenza
viru
sever
acut
respiratori
syndrom
viral
pneumonia
often
season
predilect
may
preced
viral
prodrom
inclus
fever
myalgia
sever
communityacquir
pneumonia
nonproduct
cough
headach
pregnanc
obes
chronic
diseas
advanc
age
immunosuppress
risk
factor
sever
ill
develop
complic
nearli
patient
cap
proven
bacteri
pneumonia
coinfect
viru
often
unclear
viral
organ
primari
caus
pathogen
predispos
patient
secondari
bacteri
infect
secondari
bacteri
infect
report
patient
requir
critic
care
admiss
pandem
streptococcu
pneumonia
st
aureu
h
influenza
common
pathogen
isol
patient
addit
viru
mix
infect
thought
induc
sever
inflammatori
respons
comparison
individu
pathogen
variabl
overlap
sign
symptom
occur
although
biomark
creactiv
protein
crp
significantli
rais
bacteri
diseas
insuffici
sensit
specif
use
sole
diagnost
indic
aid
differenti
bacteri
viral
pneumonia
multiplex
polymeras
chain
reaction
pcr
assay
enabl
concurr
recognit
multipl
virus
gold
standard
diagnost
test
routin
use
assay
substanti
progress
epidemiolog
knowledg
respiratori
virus
pcr
may
perform
nose
throat
swab
nasopharyng
tracheal
aspir
infect
pathogen
usual
associ
hospitalacquir
pneumonia
hap
emerg
caus
cap
healthcareassoci
pneumonia
hcap
pneumonia
develop
patient
recent
contact
healthcar
system
tabl
distinguish
cap
environ
infect
develop
also
caus
pathogen
involv
hcap
often
caus
mrsa
multidrug
resist
mdr
gramneg
pathogen
pseudomona
aeruginosa
klebsiella
pneumonia
hcap
associ
increas
sever
pneumonia
excess
mortal
due
effect
infect
mdr
pathogen
also
age
rel
poor
function
statu
relat
treatment
restrict
tend
affect
gener
investig
perform
aid
diagnosi
identifi
caus
pathogen
assess
sever
identifi
complic
monitor
respons
treatment
investig
guid
sever
pneumonia
previou
antibiot
therapi
comorbid
ill
epidemiolog
factor
chest
radiographi
cxr
firstlin
imag
modal
sever
cap
bacteri
viral
pathogen
may
induc
wide
rang
cxr
chang
multilobar
consolid
often
seen
inalthough
restrict
topneumonia
involv
legionella
streptococci
staphylococci
spp
staphylococcu
pneumonia
may
present
cavit
pneumothorac
wherea
camrsa
may
associ
rapidli
enlarg
effus
chest
ultrasound
use
confirm
presenc
effus
empyema
may
also
assist
identifi
presenc
pneumothorax
fluid
overload
comput
tomographi
ct
thorax
consid
sever
infect
patient
fail
improv
least
case
caus
pathogen
isol
routin
microbiolog
investig
sever
cap
includ
microscopi
quantit
cultur
sputum
sampl
blood
cultur
pcr
direct
immunofluoresc
respiratori
tract
sampl
urinari
legionella
pneumococc
antigen
test
serum
pneumococc
antigen
may
also
detect
report
sensit
urin
antigen
test
sensit
blood
cultur
remain
posit
even
patient
expos
appropri
antibiot
therapi
howev
note
legionella
urin
antigen
test
detect
serogroup
respons
cap
due
legionella
speci
therefor
may
provid
fals
reassur
inform
gener
rule
urin
antigen
test
use
rule
rather
rule
diseas
neg
test
result
specif
pathogen
may
sensit
earli
infect
thu
falseneg
result
uncommon
hiv
test
consid
patient
posit
streptococcu
pneumonia
sever
diseas
atyp
featur
present
serolog
assay
may
aid
diagnosi
less
common
pathogen
c
burnetii
pcr
avail
form
part
cell
wall
fungi
includ
aspergillu
assay
avail
mean
diagnos
invas
fungal
infect
measur
procalcitonin
pct
may
help
differenti
infecti
noninfecti
caus
respiratori
failur
although
must
use
isol
pct
also
use
monitor
efficaci
antibiot
treatment
time
recognit
highrisk
patient
sever
ill
essenti
ensur
appropri
antibiot
treatment
start
promptli
physiolog
support
continu
within
appropri
set
tradit
physician
use
clinic
evalu
defin
sever
structur
sever
assess
tool
develop
assist
decisionmak
regard
critic
care
admiss
use
combin
clinic
data
nearpati
investig
biomark
assess
sever
risk
stratif
tool
use
regularli
includ
pneumonia
sever
index
psi
british
thorac
societi
bt
score
tabl
sever
communityacquir
pneumonia
score
tabl
jointli
produc
american
thorac
societi
infecti
diseas
societi
america
atsidsa
psi
extens
valid
recogn
lowrisk
patient
good
predict
need
critic
care
support
risk
stratif
score
develop
includ
smartcop
tabl
creat
help
identifi
patient
may
requir
invas
respiratori
vasopressor
support
atsidsa
smartcop
perform
well
risk
stratif
tool
identifi
patient
requir
icu
admiss
valid
requir
aim
improv
simplic
use
singl
stratif
tool
nice
recommend
use
combin
clinic
judgement
arteri
blood
ga
analysi
guid
need
critic
care
admiss
approach
use
earli
warn
score
risk
stratif
tool
resuscit
bundl
could
potenti
reduc
icu
admiss
mortal
manag
diagnosi
aggress
intervent
earli
stage
diseas
present
may
prevent
progress
multiorgan
involv
earli
appropri
parenter
antibiot
administr
demonstr
improv
patient
outcom
particularli
patient
higher
risk
death
major
patient
die
sever
cap
tend
complic
multiorgan
failur
rather
primari
respiratori
failur
alon
often
requir
renal
replac
therapi
invas
circulatori
monitor
support
adher
protocol
produc
bt
idsaat
associ
reduct
overal
mortal
respiratori
patient
respiratori
failur
despit
highflow
oxygen
therapi
manag
noninvas
ventil
niv
invas
ventil
niv
particular
benefit
patient
immunosuppress
underli
obstruct
lung
diseas
pneumocysti
jiroveci
infect
lower
pa
fio
ratio
bilater
alveolar
infiltr
suggest
acut
respiratori
distress
syndrom
ard
independ
predictor
niv
failur
patient
group
progress
invas
mechan
ventil
consid
earli
stage
earli
sever
communityacquir
pneumonia
identif
fail
niv
trial
import
sever
trial
demonstr
poorer
outcom
patient
requir
intub
prolong
unsuccess
niv
trial
patient
sever
cap
requir
intub
mechan
ventil
particularli
presenc
persist
hypoxaemia
sever
acidosi
depress
conscious
progress
hypercapnia
patient
manag
lungprotect
ventil
strategi
use
low
tidal
volum
ml
kg
predict
bodi
weight
plateau
airway
pressur
cm
h
although
high
peep
level
may
improv
oxygen
mortal
differ
comparison
ventil
use
low
peep
except
ard
pa
fio
ratio
mm
hg
advanc
respiratori
rescu
techniqu
includ
prone
ventil
extracorpor
carbon
dioxid
remov
ecco
r
extracorpor
membran
oxygen
ecmo
consid
case
refractori
hypoxaemia
symptomat
hypercarbia
hypotens
manag
accord
surviv
sepsi
guidelin
fluid
resuscit
vasopressor
inotrop
support
guid
clinic
assess
combin
dynam
flow
monitor
includ
puls
contour
analysi
devic
transoesophag
doppler
transthorac
echocardiographi
standard
care
patient
includ
adher
ventilatoracquir
pneumonia
catheterrel
bloodstream
infect
bundl
nutrit
support
deep
venou
thrombosi
gastric
ulcer
prophylaxi
chest
physiotherapi
steroid
routin
recommend
adjunct
therapi
hypoxaem
respiratori
failur
except
p
jiroveci
pneumonia
current
insuffici
evid
support
use
either
gcsf
statin
antibiot
therapi
usual
begun
empir
basi
base
sever
ill
often
guid
sever
score
bt
fig
nice
guidelin
patient
risk
factor
local
epidemiolog
resist
organ
initi
treatment
broad
spectrum
aim
provid
cover
pneumonia
st
aureu
legionella
gramneg
bacteria
coverag
atyp
bacteria
mdr
pathogen
consid
risk
factor
pathogen
present
tabl
atyp
mdr
pathogen
common
patient
requir
icu
care
patient
sever
cap
treat
combin
antibiot
therapi
includ
macrolid
improv
surviv
rate
compar
monotherapi
empir
macrolid
monotherapi
avoid
due
emerg
pneumococc
resist
pathogen
identifi
antibiot
coverag
narrow
unless
concern
dual
pathogen
infect
approach
associ
fewer
complic
reduc
risk
clostridium
difficil
infect
minim
develop
antibiot
resist
sever
diseas
septic
shock
nonrespond
patient
continu
infus
timedepend
antibiot
carbapenem
may
improv
outcom
howev
elev
risk
linerel
infect
thrombophleb
preval
immunosuppress
patient
patient
admit
icu
ideal
durat
antibiot
therapi
remain
uncertain
bt
nice
guidelin
suggest
day
antibiot
treatment
initi
infect
st
aureu
gramneg
bacilli
suspect
confirm
antibiot
therapi
continu
day
cavit
pneumonia
lung
abscess
usual
treat
sever
week
shortcours
antimicrobi
therapi
potenti
improv
efficaci
minim
emerg
resist
organ
use
biomark
highli
sensit
pct
crp
may
help
reduc
durat
antibiot
treatment
without
increas
either
mortal
treatment
failur
treatment
viral
pneumonia
primarili
support
apart
patient
sever
influenza
patient
high
risk
complic
depend
current
local
influenza
rate
antivir
therapi
may
start
empir
await
viral
pcr
result
treatment
oseltamivir
zanamivir
recommend
influenza
infect
start
within
h
symptom
onset
may
reduc
durat
symptom
sever
diseas
risk
complic
aerosol
ribavirin
may
benefit
treat
respiratori
syncyti
viru
human
metapneumoviru
parainfluenza
infect
immunocompromis
patient
patient
sever
cap
often
prolong
critic
care
admiss
risk
develop
sever
septic
shock
renal
hepat
failur
coagulopathi
central
nervou
system
problem
includ
vascular
event
encephalopathi
mening
convuls
pulmonaryrel
complic
frequent
depend
infect
pathogen
sever
communityacquir
pneumonia
least
earli
use
neuromuscular
blocker
patient
sever
ard
improv
day
surviv
ventilatorfre
day
iii
lung
cavit
abscess
format
associ
infect
st
aureu
gramneg
bacilli
aspergillu
mycobacterium
nocardia
speci
failur
respond
antibiot
therapi
may
rais
possibl
noninfecti
underli
caus
vascul
bronchial
obstruct
infect
resist
bacteria
mycobacteria
fungi
iv
bacteri
influenza
pneumonia
associ
cardiacrel
complic
includ
myocardi
infarct
arrhythmia
decompens
cardiac
failur
pulmonari
inflamm
thought
trigger
cytokin
releas
upregul
inflamm
atherosclerot
plaqu
decreas
plaqu
stabil
increas
risk
ruptur
cardiac
event
associ
substanti
increas
mortal
patient
demonstr
improv
within
h
commenc
antibiot
support
care
consid
nonrespond
patient
requir
critic
care
admiss
risk
failur
respond
treatment
may
high
mortal
increas
severalfold
independ
risk
factor
failur
respond
includ
multilobar
infect
presenc
cavit
pleural
effus
liver
diseas
leucopenia
efficaci
empir
antimicrobi
may
reduc
emerg
resist
pathogen
camrsa
extend
spectrum
organ
carbapenemaseproduc
enterobacteriacea
failur
respond
treatment
result
reevalu
initi
microbiolog
result
supplementari
diagnost
test
either
escal
chang
antibiot
therapi
altern
diagnos
eosinophil
organ
pneumonia
need
also
consid
patient
slow
fail
respond
convent
treatment
possibl
undiagnos
immunosuppress
investig
histori
explor
despit
advanc
support
care
sever
cap
remain
common
reason
critic
care
admiss
associ
high
mortal
streptococcu
pneumonia
remain
common
pathogen
howev
diseas
due
gramneg
organ
frequent
patient
requir
critic
care
admiss
increasingli
mdr
despit
antibiot
stewardship
increas
surveil
research
need
elucid
extent
virus
involv
pathogenesi
sever
cap
viral
bacteri
infect
may
coexist
unclear
extent
organ
caus
diseas
predispos
patient
secondari
infect
futur
develop
within
field
like
concentr
diagnost
abil
identifi
caus
pathogen
within
shorter
timefram
